What happened
Transcatheter tricuspid repair cuts death or HF hospitalization ~60% versus medical therapy.
“Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.”
Quoted in ACC Journal Scan ↗
Tricuspid repair finally shows it improves mortality and HF hospitalization, not just symptoms.
Thamman calls TRIC-I-HF a long-awaited result showing transcatheter tricuspid repair improves mortality and HF hospitalization, not just symptoms. She adds that echo shows the device lowers TR grade for up to 3 years.
TRIC-I-HF matters clinically because it is new evidence that T TEER improves hard outcomes.
Hafiz says the trial is clinically important because it is new evidence that T TEER can improve hard outcomes. He highlights 3-year freedom from death or heart-failure hospitalization of 52.4% versus 21.0% (HR, 0.40).
A major step forward in managing severe tricuspid regurgitation in HF patients.
Recio calls the trial a major step forward for severe tricuspid regurgitation in HF. He points to fewer HF hospitalizations, marked improvement in NYHA class and quality of life (KCCQ), and a favorable safety profile.
Repair plus medical therapy beats medicines alone, with an NNT of 4 at 1 year.
Nemshah lists a win ratio of 2.42, an NNT = 4 at 1 year, 38% lower all-cause mortality (p=0.027), and significant quality-of-life improvement with repair plus medical therapy in severe TR.
The trial asks whether treating severe TR changes prognosis, and answers yes.
Alania frames the question as whether treating severe TR can change prognosis, not just symptoms. He notes that in 360 high-risk patients, transcatheter repair plus medical therapy improved the hierarchical outcome and reduced death or HF hospitalization.
Asher outlines the population: 360 patients with symptomatic severe tricuspid regurgitation and high heart-failure risk, mean age 80, 56.4% women, randomised 2:1.
X post ↗
“@MAnisHaider @jtsaxon One important correction. Baseline TR severity was greater in TRILUMINATE than in TRICI-HF… by a good amount.”
X ↗Open questions from this trial that would benefit from expert input.
Answers are grounded in this paper and cite their sources.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Significant tricuspid regurgitation is common in heart failure and carries a poor prognosis, but whether intervening on the valve improves outcomes beyond medical therapy remains uncertain. TRIC-I-HF tested tricuspid valve intervention in this population.
Does transcatheter tricuspid-valve repair plus medical therapy improve a composite of death, heart failure hospitalization, and quality of life in patients with symptomatic severe tricuspid regurgitation?
| Outcome | TV repair | Medical |
|---|---|---|
| Death, HF hospitalization, QoL improvement (hierarchical, 1 yr) First primary · win ratio 2.42 (95% CI 1.76–3.33; p<0.001) favoring repair; per-arm values not reported | ||
| Freedom from death or HF hospitalization through 3 years Second primary · HR 0.40 (95% CI 0.29–0.55; p<0.001) for death or HF hospitalization | TV repair 52.4% | Medical 21.0% |
Does transcatheter tricuspid-valve repair plus medical therapy improve a composite of death, heart failure hospitalization, and quality of life in patients with symptomatic severe tricuspid regurgitation?
Transcatheter tricuspid-valve repair added to medical therapy significantly improves a hierarchical composite of death, heart failure hospitalization, and quality of life at 1 year, and reduces death or heart failure hospitalization through 3 years in patients with severe tricuspid regurgitation.
Experts read TRIC-I-HF as practice-changing: catheter repair of a severely leaking tricuspid valve, added to medicines, appears to help patients live longer and stay out of hospital, not just feel better.
Clinicians posting about the trial welcome it as the first strong evidence that fixing a leaky tricuspid valve through a catheter improves survival and hospital stays, not only symptoms. Reactions are uniformly positive, and no one publicly disputes the result. What's still open is how widely the result applies, since this was an older, high-risk heart failure group.
Several clinicians make the same point: treating severe tricuspid regurgitation with a catheter procedure now shows benefit on hard outcomes like death and heart failure hospitalization, not just symptoms.
1 take classified by contention axis so far — the map appears as more land.
Supports transcatheter tricuspid repair plus medical therapy in symptomatic severe tricuspid regurgitation; delivers first randomized evidence of hard-endpoint benefit.
BackgroundThe effect of transcatheter tricuspid-valve repair on clinical outcomes, including death and hospitalization for heart failure, in patients with severe tricuspid regurgitation remains uncertain. MethodsWe randomly assigned patients with symptomatic severe tricuspid regurgitation and an increased risk of future heart-failure events in a 2:1 ratio to tricuspid-valve repair plus medical therapy (tricuspid-repair group) or medical therapy alone (medical-therapy group). The first primary end point was a hierarchical composite of death from any cause, hospitalization for heart failure, and quality-of-life improvement at 1 year, assessed by win ratio. If the between-group difference was significant, a second primary end point would be tested: a composite of death from any cause or hospitalization for heart failure through 3 years. ResultsA total of 360 patients underwent randomization (237 patients were assigned to the tricuspid-repair group and 123 to the medical-therapy group). The mean (±SD) age of the patients was 80.3±6.4 years, and 56.4% were women. The win ratio for the first primary end point was 2.42 (95% confidence interval [CI], 1.76 to 3.33; P<0.001), favoring tricuspid-valve repair. The Kaplan–Meier estimate for freedom from death from any cause or hospitalization for heart failure (second primary end point) through 3 years was 52.4% (95% CI, 43.2 to 63.6) in the tricuspid-repair group and 21.0% (95% CI, 12.7 to 34.6) in the medical-therapy group (hazard ratio for death from any cause or hospitalization for heart failure, 0.40; 95% CI, 0.29 to 0.55; P<0.001). Major adverse events within 30 days occurred in 14 patients (5.9%) in the tricuspid-repair group. ConclusionsAmong patients with symptomatic severe tricuspid regurgitation, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone with respect to a hierarchical composite of death from any cause, hospitalization for heart failure, and quality-of-life improvement at 1 year and was also associated with a lower risk of a composite of death from any cause or hospitalization for heart failure through 3 years. (Funded by the German Center for Cardiovascular Research and others; TRIC-I-HF ClinicalTrials.gov number, NCT04634266.)
NEJM · ESC 2026 · RCT. Transcatheter repair of severe tricuspid regurgitation cuts death or HF hospitalization. TRIC-I-HF: Tricuspid-Valve Intervention in Heart Failure 360 patients: Symptomatic severe tricuspid regurgitation, mean age 80.3. Randomized, followed up to 3 years: Transcatheter repair plus medication vs Medical therapy alone. Freedom from death or HF hospitalization, 3 years: TV repair 52.4% vs Medical 21.0%. HR 0.40 (95% CI 0.29–0.55), P<0.001. Hazard ratio for death or HF hospitalization. 5.9% major adverse events: Within 30 days of the repair procedure. Bottom line: First randomized hard-endpoint evidence supports repair plus medical therapy in symptomatic severe tricuspid regurgitation.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Hausleiter et al. (2026) conducted an RCT in symptomatic severe tricuspid regurgitation (n=360). transcatheter tricuspid-valve repair plus medical therapy vs. medical therapy alone was evaluated on hierarchical composite of death from any cause, hospitalization for heart failure, and quality-of-life improvement at 1 year (Win Ratio 2.42, 95% CI 1.76-3.33, p=<0.001). Transcatheter tricuspid-valve repair was superior to medical therapy for a composite of death, heart failure hospitalization, and quality of life (Win Ratio 2.42; 95% CI 1.76-3.33; P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context:
